MiniMed Group (NASDAQ:MMED) Reaches New 1-Year High on Analyst Upgrade

MiniMed Group Inc (NASDAQ:MMED)’s stock price reached a new 52-week high during mid-day trading on Tuesday after Citigroup raised their price target on the stock from $23.00 to $26.00. Citigroup currently has a buy rating on the stock. MiniMed Group traded as high as $21.86 and last traded at $21.0940, with a volume of 387936 shares. The stock had previously closed at $20.26.

Other research analysts have also issued reports about the stock. Benchmark reissued a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th. Weiss Ratings upgraded shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Piper Sandler restated a “neutral” rating and issued a $16.00 target price on shares of MiniMed Group in a report on Thursday, June 4th. UBS Group increased their price target on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday. Finally, BTIG Research upped their price objective on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.62.

MiniMed Group News Roundup

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of approximately $843 million, up 17% year over year, with organic U.S. growth accelerating to 13% and international sales rising 18% as reported. The company also raised its fiscal-year organic revenue-growth guidance. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Management highlighted progress across its product pipeline, including an FDA submission for MiniMed Fit™, CE Mark approval for MiniMed Flex™, completion of the Vivera™ FCL U.S. pivotal trial enrollment and IDE approval for a next-generation extended-wear sensor. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Several firms raised their targets following the sales report. Citigroup and Wells Fargo moved to $26, while UBS raised its target to $28 and maintained a “buy” rating. Mizuho also set a $26 target with an “outperform” rating; Bank of America and BTIG raised their targets to $28 and reiterated “buy” ratings. These revisions signal improving analyst confidence in MiniMed’s growth outlook. These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results
• Neutral Sentiment: The reported brokerage consensus target of $21.62 remains below the latest trading level, suggesting that some analysts’ estimates may not yet reflect the newest quarterly results and upgrades. MiniMed Group Receives Consensus Target Price from Brokerages

Institutional Trading of MiniMed Group

Several institutional investors and hedge funds have recently made changes to their positions in MMED. California State Teachers Retirement System purchased a new stake in shares of MiniMed Group during the second quarter valued at $89,000. Legal & General Group Plc bought a new stake in MiniMed Group during the 2nd quarter valued at about $91,000. The Manufacturers Life Insurance Company purchased a new stake in MiniMed Group in the 2nd quarter valued at about $185,000. Punch & Associates Investment Management Inc. bought a new position in MiniMed Group in the 2nd quarter worth about $292,000. Finally, Washington Growth Strategies LLC purchased a new stake in shares of MiniMed Group in the second quarter valued at approximately $397,000.

MiniMed Group Trading Up 6.0%

The stock has a 50 day moving average of $17.84. The stock has a market capitalization of $6.68 billion and a P/E ratio of -34.94.

MiniMed Group (NASDAQ:MMED) last issued its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. MiniMed Group’s revenue was up 15.6% on a year-over-year basis. Sell-side analysts predict that MiniMed Group Inc will post 0.66 EPS for the current fiscal year.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.